603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Autor:	Shubham Pant, Christopher Moy, A. Santiago-Walker, G. Vasudeva Iyer, Javier Garcia-Corbacho, Olaf Witt, Martin Schuler, Shukui Qin, Y.Y. Lau, Qi Xia, Darren Hargrave, Christophe Massard, J. Tabernero, Toshihiko Doi, C. Hammond, C. Lu-Emerson, S. Little, Hussein Sweiti
Rok vydání:	2020
Předmět:	Oncology Open label study Erdafitinib business.industry Fibroblast growth factor receptor Cancer research Medicine Hematology business Gene
Zdroj:	Annals of Oncology. 31:S502-S503
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.717
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::077528ca849f64f616630b30a28d4031 https://doi.org/10.1016/j.annonc.2020.08.717 Zobrazit plný text záznamu